HealthCare Global Enterprises (HCG) investor relations material

Executive summary

• Achieved revenue of INR 6,951 million in Q1 FY27, up 13% year-over-year, with broad-based growth across all regions and specialties.

• Adjusted EBITDA rose 20% year-over-year to INR 1,339 million, with margin improvement to 19.4% from 18.2% in Q1 FY26.

• Profit after tax surged 190% year-over-year to INR 138 million, with PAT margin at 2.0%.

• Strategic milestones include divestment of the fertility business, successful rights issue, and commissioning of North Bangalore hospital.

• North Bangalore hospital commenced operations, adding over 120 beds and advanced MR-LINAC technology.

Financial highlights

• Q1 revenue grew 13% year-over-year to INR 6,951 million; patient volumes increased 11%, ARPOB up 2%.

• Adjusted EBITDA (excluding North Bangalore losses and one-offs) up 20% year-over-year to INR 1,339 million, margin improved to 19.4% from 18.2%.

• Non-institutional business revenue grew 17% year-over-year, with its contribution rising from 67% to 69%.

• Reported EBITDA was INR 1,223 million, impacted by North Bangalore start-up losses and EPCG provision.

• Consolidated net profit after tax and exceptional items was Rs. 1,646 lakhs, up from Rs. 598 lakhs year-over-year.

Outlook and guidance

• Confident in delivering mid-teen revenue growth from existing and new centers, with a focus on margin improvement.

• Long-term EBITDA margin target is 24%-25% in four to five years; 21%-22% expected in the next two years.

• Targeting addition of 1,000 beds by FY30, with 60% through brownfield expansion and significant capex planned.

• North Bangalore hospital expected to reach optimal utilization (60%-65%) in 3-4 years and monthly breakeven within the year.

• Strategic priorities include optimizing the existing network, improving efficiency, investing in growth, and enhancing patient experience.